TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
暂无分享,去创建一个
Eva Hellström-Lindberg | Brigitte Schlegelberger | Anette Hedlund | G. Mufti | L. Saft | M. Jädersten | A. Porwit | E. Hellström-Lindberg | B. Schlegelberger | G. Göhring | Anna Porwit | Gudrun Göhring | Martin Jädersten | Leonie Saft | Alexander Smith | Austin Kulasekararaj | Sabine Pomplun | Robert Hast | Ghulam J Mufti | A. Kulasekararaj | R. Hast | S. Pomplun | Alexander Smith | A. Hedlund
[1] B. Quesnel,et al. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. , 1994, Leukemia.
[2] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Fenaux,et al. Rearrangement and expression of the p53 gene in myelodysplastic syndrome and acute myeloid leukemia. , 1990, Nouvelle revue francaise d'hematologie.
[4] L. Saft,et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression , 2009, Haematologica.
[5] A. Warren,et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q− syndrome , 2009, Nature Medicine.
[6] S. Yagihashi,et al. Apoptosis, bcl-2 Expression and p53 Accumulation in Myelodysplastic Syndrome, Myelodysplastic-Syndrome-Derived Acute Myelogenous Leukemia and de novo Acute Myelogenous Leukemia , 1999, Acta Haematologica.
[7] B. Quesnel,et al. p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .
[8] D. J. King,et al. p53 mutation in the myelodysplastic syndromes , 1995, British journal of haematology.
[9] E. Wattel,et al. Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy. , 1994, Leukemia.
[10] S. Misawa,et al. TP53 mutations in myelodysplastic syndrome. , 1996, Leukemia & lymphoma.
[11] E. Wattel,et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. , 1995, Leukemia.
[12] J. Yokota,et al. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. , 1995, Leukemia research.
[13] M. Kitagawa,et al. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. , 1994, The American journal of pathology.
[14] J. Boultwood,et al. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). , 2004, Haematologica.
[15] M. Kahsai,et al. p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[16] What does apoptosis have to do with clinical features in myelodysplastic syndrome? , 2002, Haematologica.
[17] S. Chevret,et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.
[18] A. List. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). , 2005, Seminars in oncology.
[19] R. Larson,et al. RAS, FLT3, and TP53 mutations in therapy‐related myeloid malignancies with abnormalities of chromosomes 5 and 7 , 2004, Genes, chromosomes & cancer.
[20] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[21] E. Hellström-Lindberg,et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression , 2010, Annals of Hematology.
[22] D. Christiansen,et al. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Taniwaki,et al. Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic Syndrome , 2003, Leukemia & lymphoma.
[24] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.
[25] H. Kaneko,et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.
[26] A. Schulz,et al. P53 mutations in myelodysplastic syndromes. , 1992, Leukemia.
[27] T. Murate,et al. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia , 2008, Pathology international.
[28] A. List,et al. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes , 2007, Current opinion in hematology.
[29] G. Mufti,et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Taniwaki,et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.
[31] S. Green,et al. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. , 2006, Cancer control : journal of the Moffitt Cancer Center.